

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/084,139	02/28/2002	Shigekazu Nagata	1110-0307P	7006	
2292	7590 09/21/2	7590 09/21/2004		EXAMINER	
BIRCH ST PO BOX 74	EWART KOLASC	O HARA, EILEEN B			
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER	
	,		1646		
			DATE MAILED: 09/21/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

en e	Application No.	Applicant(s)				
	10/084,139	NAGATA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Examiner Eileen O'Hara	1646				
The MAILING DATE of this communicati						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR A THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communicated. If the period for reply specified above is less than thirty (30) day. If NO period for reply is specified above, the maximum statutory. Failure to reply within the set or extended period for reply will, be any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	FION. CFR 1.136(a). In no event, however, may a roution. ys, a reply within the statutory minimum of third y period will apply and will expire SIX (6) MON by statute, cause the application to become AE	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed or	Responsive to communication(s) filed on					
2a) This action is FINAL . 2b)	This action is FINAL . 2b) This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1-15 is/are pending in the application 4a) Of the above claim(s) is/are with 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-15 are subject to restriction and	ithdrawn from consideration.					
Application Papers						
9) The specification is objected to by the Ex						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection		• •				
Replacement drawing sheet(s) including the 11) The oath or declaration is objected to by	- · · · · · · · · · · · · · · · · · · ·	• • • • • • • • • • • • • • • • • • • •				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International E * See the attached detailed Office action for	uments have been received. uments have been received in A e priority documents have been Bureau (PCT Rule 17.2(a)).	pplication No received in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-943) Information Disclosure Statement(s) (PTO-1449 or PTO/Paper No(s)/Mail Date	48) Paper No(s	Summary (PTO-413) s)/Mail Date nformal Patent Application (PTO-152)				

Application/Control Number: 10/084,139

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-7 and 15, in so far as they are drawn to a method of treating an ischemic reperfusion injury or disease based thereon comprising administering a Fas antagonist, classified in class 514, subclass 1.
- II. Claims 8,9 and 15, in so far as they are drawn to method of treating graft versus host disease comprising administering a Fas antagonist, classified in class 514, subclass 1.
- III. Claims 10-12 and 15, in so far as they are drawn to a method of treating an organ injury comprising administering a Fas antagonist, classified in class 514, subclass1.
- IV. Claims 13 and 14, drawn to a method of preserving an organ comprising contacting the organ with a solution comprising an effective amount of a Fas antagonist, classified in class 435, subclass 1.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-IV are related in that they are methods of treatment with a Fas antagonist, however, inventions I-III are methods of treating either a reperfusion injury or disease based thereon, graft versus host disease or organ injury, which are methods of treating different patient populations which would require different searches and which would be a burden. Additionally,

Application/Control Number: 10/084,139

Art Unit: 1646

the method of preserving an organ of invention IV would require different method steps and equipment, and has a different purpose from the other methods.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification or separate search requirements, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878. The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached at (571) 272-0961.

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1646

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.ispto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Eileen B. O'Hara, Ph.D.

Patent Examiner

EILEEN B. O'HARA
PATENT EXAMINER

Elen B.O Wara